Feb 22, 2021 10:00am
Beyond clinical and commercial manufacturing, Catalent also had a hand in developing the encapsulation process for Aurinia Pharmaceuticals drug Lupkynis. (Catalent)
Just weeks after Aurinia Pharmaceuticals bagged its first FDA green light, the company is turning to one of its clinical manufacturing partners to help bring its drug to market.
Aurinia enlisted Catalent to deliver commercial supply of its oral lupus nephritis drug Lupkynis (voclosporin), the CDMO said Thursday. The multiyear pact follows Lupkynis January green light and the companies successful team-up in the clinic.
Catalent is set to manufacture the drug as a softgel capsule at its site in St. Petersburg, Florida. The 435,000-square-foot facility, chief among the CDMO s North American softgel operations, boasts capacity to turn out 18 billion capsules per year, Catalent said in a release.
Bain Capital and Cinven are acquiring Lonza's Specialty Ingredients division in a deal worth $4.7 billion, the Swiss contract drug maker said on Monday, as it focuses on its faster-growing unit that supplies drug and biotech companies.
By Reuters Staff
2 Min Read
ZURICH (Reuters) - Bain Capital and Cinven are acquiring Lonza’s Specialty Ingredients division in a deal worth $4.7 billion, the Swiss contract drug maker said on Monday, as it focuses on its faster-growing unit that supplies drug and biotech companies.
The Bain-Cinven consortium had been listed with Germany’s Lanxess and buyout groups Advent, Carlyle and others as bidders for the unit that makes anti-dandruff shampoo ingredients, nutritional supplements for swine and microbial controls for wood and hygiene products.
Lonza, which said the enterprise value of the transaction is 4.2 billion Swiss francs ($4.7 billion), is doubling down on its accelerating drug business. Its customers include Moderna, which Lonza supplies with ingredients for its COVID-19 vaccine, and AstraZeneca, which hired the Swiss company to help make its COVID-19 antibody treatment.
(2)
Lonza Signs Agreement to Divest Specialty Ingredients Business to Bain Capital and Cinven
Lonza Specialty Ingredients to be sold to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion
Divestment will allow Lonza to refocus its business as a pure-play partner to the healthcare industry
Successful track record of investment in industrials sector and portfolio companies confirms that Bain Capital and Cinven are the right home for the business
Smooth transition for employees and customers is a priority for both seller and buyers. The transaction is anticipated to close in H2 2021
Quote from Albert Today s announcement is the result of a comprehensive and robust selection process.
EXPLAINER: Why it s hard to make vaccines and boost supplies lmtonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lmtonline.com Daily Mail and Mail on Sunday newspapers.